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Cancer stem cells (CSCs) are proposed to drive
tumor initiation and progression. Yet, our under-
standing of the cellular and molecular mechanisms
that underlie CSC properties is limited. Here we
show that the activity of TAZ, a transducer of the
Hippo pathway, is required to sustain self-renewal
and tumor-initiation capacities in breast CSCs. TAZ
protein levels and activity are elevated in prospective
CSCs and in poorly differentiated human tumors and
have prognostic value. Gain of TAZ endows self-
renewal capacity to non-CSCs. In epithelial cells,
TAZ forms a complex with the cell-polarity determi-
nant Scribble, and loss of Scribble—or induction
of the epithelial-mesenchymal transition (EMT)—
disrupts the inhibitory association of TAZ with the
core Hippo kinases MST and LATS. This study links
the CSC concept to the Hippo pathway in breast
cancer and reveals amechanistic basis of the control
of Hippo kinases by cell polarity.
INTRODUCTION
Human tumors disproportionally arise in tissues and organs that
undergo constant remodeling and regeneration. As these
processes are normally maintained by stem cells, this has led
to the attractive hypothesis that tumor initiation and progression
are also driven by cancer stem cells (CSCs), here defined as the
fraction of tumor cells specifically endowed with self-renewal
and tumor-seeding potential and ability to spawn non-CSCprogeny (Visvader and Lindeman, 2008). The definition of
CSCs remains largely operational, i.e., based on functional
assays that register self-renewal in vitro and tumor initiation
in vivo (Gupta et al., 2009). In fact, we have only a scattered
understanding of the molecular and cellular mechanisms that
are responsible for the special attributes of CSCs.
In breast cancer, tumor cells can be physically separated in at
least two distinct populations, one of which is enriched with
CSCs (Visvader and Lindeman, 2008). Malignant progression is
accompanied by an increased proportion of these CSCs within
the tumor (Pece et al., 2010) and activation of the epithelial-to-
mesenchymal transition (EMT) (Chaffer and Weinberg, 2011;
Gupta et al., 2009). EMT is a complex transdifferentiation
program that is instrumental for the acquisition of stemness by
nontransformed and tumor cells (Mani et al., 2008; Thiery
et al., 2009). Although EMT is rarely observed in vivo (Chaffer
andWeinberg, 2011; Savagner, 2010), one of its central features,
namely loss of cell polarity, is a fundamental histopathological
trait ofmost human cancers (Thiery et al., 2009). Themechanistic
relationship between EMT, loss of cell polarity, and CSC charac-
teristics remains an open question in cancer biology. Here we
report the identification of TAZ, a transcriptional effector of
the Hippo signaling cascade (Pan, 2010), as molecular thread
between these events.RESULTS
TAZ/YAP Activity Correlates with High Histological
Grade and Metastasis in Breast Cancer
We initiated this study with the aim to identify signaling pathways
driving tumorigenesis and tumor heterogeneity in human breast
cancer. Importantly, these traits have been traced to the CSCCell 147, 759–772, November 11, 2011 ª2011 Elsevier Inc. 759
Figure 1. TAZ/YAP Activity Correlates with High Histological Grade and Stem Cell Content in Breast Cancers
(A) Enrichment of gene signatures in the list of genes preferentially expressed in G3 versus G1 tumors in the metadataset. Left: Scheme of the computational
procedure used to generate the data reported on the right (see text). Right: Numbers indicate p values (corrected for multiple tests) for significance of the
enrichment. Signatures significantly enriched in G3 tumors (p value < 0.05) are indicated in bold. ‘‘No overlap’’ indicates the absence of genes in common
between the indicated signature and the genes overexpressed in G3 tumors. See the Extended Experimental Procedures for details on the statistical methods
and references for gene signatures.
(B) Average gene-expression values of signatures for normal mammary (hNMSC), breast cancer (IGS, CD44high), and embryonic (ES1, ES2, ES-like) stem cells in
breast tumor samples stratified according to histological grading. G2 tumors were stratified in two groups according to high or low expression of the TAZ/YAP
signature. Average gene-expression values of the TAZ/YAP signature (lane 1) are shown as control of the procedure. Data are shown as mean ± standard error of
the mean (SEM).
(C) Kaplan-Meier graphs representing the probability of cumulative metastasis-free survival in breast cancer patients from the metadataset stratified according
to the TAZ/YAP signature. The log-rank test p value reflects the significance of the association between TAZ/YAP signature ‘‘low’’ and longer survival.
See also Figure S1 and Table S1.subpopulation (Pece et al., 2010; Visvader and Lindeman, 2008).
Indeed, CSCs are enriched in high-grade breast cancers (i.e.,
poorly differentiated tumors classified as G3 by histopatholog-
ical criteria) when compared to well-differentiated, low-grade
(G1) tumors (Pece et al., 2010). We thus based our initial analysis
on clinical data and reasoned that if a given signaling cascade is
relevant for amplification/activity of CSCs, this pathway should
be identifiable by the specific upregulation of its target genes760 Cell 147, 759–772, November 11, 2011 ª2011 Elsevier Inc.(gene signature) in G3 versusG1 tumors (Figure 1A, left diagram).
For this, we generated a compendium of data (metadataset)
from seven independent breast cancer gene-expression data-
sets that contained information on histological grading. This
cohort of 993 primary tumors was analyzed by the significance
analysis of microarrays (SAM) algorithm to identify a list of genes
differentially expressed in G3 versus G1 tumors. This identified
78 Affymetrix probesets specifically upregulated more than
two times in G3 cancers and that showed 99.9% of statistical
confidence for differential expression (Table S1 available online).
We then used a computational enrichment analysis to test
whether the G3-enriched gene set included a higher-than-
randomly-expected representation (expected p value < 0.05) of
gene signatures that denote the activity of individual signal
transduction pathways (Figure 1A, left diagram). In particular,
we screened for associations with signatures registering the
activity of ERBB2, RAS, Notch, TGF-b, Wnt/b-catenin, Src,
STAT3, NF-kB, and Hippo signaling pathways in human
mammary cell lines (See Extended Experimental Procedures).
Strikingly, the only signatures significantly over-represented in
G3 breast cancers were those denoting the activity of the Hippo
transducers TAZ and YAP (Figure 1A). The same result was
obtained using an independent dataset from the Netherland
Cancer Institute (NKI) (van de Vijver et al., 2002) that was not
included in our metadataset (Figure S1A). These findings indi-
cate that tumors classified as poorly differentiated/high grade
by histopathological criteria display elevated TAZ/YAP activity.
As previously reported, G3 breast tumors are also characterized
by expression of embryonic and normal mammary stem cell
signatures (Ben-Porath et al., 2008; Pece et al., 2010) (Figures
1A and 1B), suggesting that TAZ/YAP activity correlates with
stemness potential. To reinforce this link, we turned our attention
on themost heterogeneous category of breast cancer, that is, G2
tumors, whose characteristics in terms of gene expression and
clinical outcome vary from being similar to G1 to being closer
to G3 (Ivshina et al., 2006). We stratified G2 patients from our
metadataset in two categories according to high or low expres-
sion levels of TAZ/YAP target genes and found that G2 tumors
with high TAZ/YAP activity are associated with an enrichment
of stem cell signatures (Figure 1B).
Because metastasis is intimately wired to tumor-initiating
capacity of a primary tumor (Chaffer and Weinberg, 2011),
we tested whether TAZ/YAP activity was associated to this
event in human patients’ datasets. As shown by univariate
Kaplan-Meier analyses, tumors with high expression of the
TAZ/YAP signature displayed a significantly higher probability
to develop metastasis and reduced survival compared to
tumors characterized by low TAZ/YAP activity (Figures 1C
and S1B). Taken together, the data support the notion that acti-
vation of TAZ or YAP specifically parallels tumor traits previously
linked to their CSC content, such as high histological grade,
expression of stem cells signatures, tumor heterogeneity, and
metastasis.
TAZ Is Required to Sustain Self-Renewal and
Tumorigenic Potential of Breast Cancer Cells
We next sought to determine whether TAZ/YAP activity plays
a causal role in defining CSC traits. As amodel of tumor progres-
sion, we used two isogenic derivatives of the human mammary
MCF10A cell line: Ras-transformedMCF10A-T1k cells (hereafter
MII) and their malignant derivative, MCF10A-CA1a cells (also
known as MIV), derived from in vivo spontaneous evolution of
MII cells (Santner et al., 2001). Once injected orthotopically in
the fat pad of immunocompromized mice, MII cells generate
low-grade tumors, whereas MIV cells form high-grade tumors,
resembling G3 tumors (Figure 2A).To validate MII and MIV as a model of increased CSC content
during breast cancer progression (Pece et al., 2010), we
compared their self-renewal potential, as assayed by the
capacity to form and propagate mammospheres in vitro and
to give rise to tumors in vivo when transplanted in the mouse
fat pad (Dontu et al., 2003; Visvader and Lindeman, 2008).
Once cultured in suspension, MIV cells formed more primary
and six times more secondary mammospheres than MII cells
(Figure 2B). The sphere-forming capacity in subsequent serial
passages remained stable for MIV cells but declined for MII cells
(Figure 2B and data not shown). In order to measure tumorige-
nicity, we injected orthotopically 104 and 106 MII or MIV cells.
Although both concentrations of MIV cells readily formed
tumors in all injected mice, MII-derived tumors were detected
only in one-third of mice injected with 106 cells but not at the
lower cell concentration (Figure S2A). Thus, MII and MIV cells
are endowed with significantly different self-renewal and tumor-
igenic potential, recapitulating the differences in CSC represen-
tation previously reported for G1 versus G3 tumors (Pece et al.,
2010).
We then asked whether the differences in these CSC-related
properties could be ascribed to differential expression of TAZ
and/or YAP between MII and MIV cells. Intriguingly, western
blot analyses showed that TAZ levels are higher in MIV than in
MII cells, whereas YAP is expressed similarly in both cell lines
(Figure 2C). Moreover, levels of TAZ in MIV cells were compa-
rable to those in MDA-MB-231 cells (Figure 2C), one of the
most established model systems of aggressive breast cancer
(Adorno et al., 2009).
To directly address the role of TAZ as a determinant of
self-renewal, we knocked down endogenous TAZ in MIV cells
by shRNA. TAZ knockdown strongly downregulated the expres-
sion of Survivin and CTGF, known TAZ/YAP target genes (Pan,
2010) (Figure 2D), but had no overt effects on cell viability and
proliferation in 2D cultures (data not shown). Remarkably,
however, MIV-shTAZ formed significantly less primary and
secondary mammospheres than control MIV cells (MIV-shCon-
trol) (Figure 2E). We also noticed that the sizes of the mammo-
spheres in control and TAZ-depleted populations were surpris-
ingly similar (Figure 2F), suggesting that high levels of
endogenous TAZ in MIV cells do not primarily influence cell
proliferation duringmammosphere growth. To confirm that these
observations are not due to off-target effects of the RNAi
approach, we coinfected MIV-shTAZ with an shRNA-insensitive
mouse TAZ construct (MIV-shTAZ+mTAZ); this fully rescued
TAZ-dependent gene responses and mammosphere-forming
capacity (Figures S2B and S2C).
To assay whether TAZ regulates tumor-initiating potential of
breast cancer cells, we compared MIV-shControl and MIV-
shTAZ cells for capacity to seed tumors at limiting dilutions.
Whereas shControl cells are able to form tumors in the majority
of injected mice, even upon injection of only 20 cells, TAZ-
depleted cells showed a dramatic decrease of tumor-seeding
ability as up to 104 cells were required to induce tumors in
100% of the animals (Figures 2G and S2D). Based on these
data, it is possible to estimate that depletion of TAZ causes
about a 20-fold reduction in the number of tumor-initiating cells
(p value < 0.0001). Taken together, these in vitro and in vivoCell 147, 759–772, November 11, 2011 ª2011 Elsevier Inc. 761
Figure 2. TAZ Is Required to Sustain Self-Renewal
and Tumorigenic Potential of Breast Cancer Cells
(A) Representative hematoxylin and eosin staining of
tumors emerging after fat pad injection of RAG/ mice
with MII or MIV cell lines. MII cells form small tubular
structures with no nuclear atypia, whereas MIV cells form
large tumor masses with no tubular structures, elevated
nuclear heterogeneity, and prominent nucleoli.
(B) Quantification of primary and secondary mammo-
spheres formed by MII or MIV cells (mean + SEM of six
experiments).
(C) Western blot analysis for YAP and TAZ in lysates from
the indicated cell lines. GAPDH serves as loading control.
(D) Western blot analysis for TAZ, CTGF, and Survivin in
lysates from control (shControl) and TAZ-depleted (shTAZ)
MIV cells.
(E) Quantification of primary and secondary mammo-
spheres formed by shControl or shTAZMIV cells (p value <
0.0001). Data are presented as in (B).
(F) Representative images of primary mammospheres
formed by shControl or shTAZ MIV cells. Scale bars
represent 200 mm.
(G) Tumor-seeding ability of shControl and shTAZ MIV
cells. The indicated number of cells were injected into the
fat pads of SCID mice. Palpable tumor formation was
evaluated 3 weeks after transplantation. Results are
shown as the fraction of mice developing palpable tumors.
The complete set of data is in Figure S2D.
See also Figure S2.results indicate that TAZ is required for self-renewal and tumor
initiation of breast cancer cells.
TAZ Endows Self-Renewal Capacity to Breast Cancer
Cells
We next sought to investigate the role of TAZ as a potential
driving force for self-renewal in a pool of CSCs naturally arising
within breast cancer cells. To test this, we used fluorescence-
activated cell sorting (FACS) to sort MII cells according to
expression of the cell-surface antigen markers CD44 and
CD24; this approach has been successfully used to identify
putative CSCs contained in primary breast tumors or mammary762 Cell 147, 759–772, November 11, 2011 ª2011 Elsevier Inc.cell lines based on a CD44high/CD24low immu-
nophenotypical profile, whereas the excluded
cells represent a more differentiated tumor
progeny of limited stemness potential (Al-Hajj
et al., 2003). As shown in Figures 3A and 3B,
FACS analysis readily revealed a CD44high/
CD24low subpopulation that displayed higher
levels of TAZ protein and transcriptional activity
once compared to the remaining cell population
(CD44low/CD24low). Moreover, the CD44high/
CD24low population displays many CSC-like
properties: (1) the CD44high/CD24low cells can
regenerate the CD44low/CD24low population
but not vice versa, suggesting a lineage hier-
archy between these immunologically distinct
populations (Figures S3A–S3C); (2) CD44high/
CD24low cells are endowed with better long-
term self-renewal capacity as measured bymammosphere assays (Figure 3C); (3) CD44high/CD24low cells
include the so-called ‘‘side population (SP)’’ (Figure S3D), which
is defined by its ability to exclude the Hoechst vital dye (Dontu
et al., 2003). Collectively, these data provide evidence that cell
populations endowed with CSC properties express higher levels
of TAZ.
To establish whether TAZ is functionally relevant for the bio-
logical traits of the CD44high/CD24low population, we used three
independent shRNAs to knock down endogenous TAZ in MII
cells (Figure S3E). TAZ is required for the maintenance of the
CD44high/CD24low antigen phenotype (Figure 3D) and for primary
and secondary mammosphere formation in MII cells (Figure 3E
Figure 3. TAZ Is Required to Sustain the
Cancer Stem Cell Population
(A) Representative FACS profile of MII cells with
CD24 and CD44 markers. Inset: isotype controls.
(B) Western blot analysis for expression of TAZ,
CTGF, and Survivin in the CD44low/CD24low and
CD44high/CD24low populations from FACS-sorted
MII cells.
(C) Quantification of secondary mammospheres
formed by CD44low/CD24low and CD44high/
CD24low MII cells (mean + SEM of six experi-
ments). MII cell populations were purified by
FACS, amplified in 2D culture, and used for
mammosphere formation.
(D) Effects of TAZ depletion in MII cells. MII cells
were transduced with retroviruses encoding for
three independent shRNA sequences against TAZ
or with a control shRNA (shGFP) and analyzed by
FACS for their CD44/CD24 profiles. The efficiency
of TAZ downregulation in each cell line is shown in
Figure S3E. Left panels: Representative FACS
profiles of shGFP or shTAZ#1 MII cells. The other
two TAZ-depleted cell lines display a similar
pattern (data not shown). Right panel: Quantifica-
tion of the CD44high/CD24low population in shGFP
or shTAZ cells. Data are reported as mean + SEM.
(E) Quantification of secondary mammospheres
formed by control or TAZ-depleted MII cells. The
data are reported as in (C).
See also Figure S3.and data not shown). These findings suggest that TAZ expres-
sion is important to maintain self-renewal of prospective CSCs.
We next tested whether raising TAZ activity could establish
self-renewal properties. To this end, we overexpressed in MII
cells a constitutive active point mutant of TAZ, TAZ(S89A)
(Pan, 2010), and confirmed that it induced the expression
of TAZ target genes (Figure S4A). By flow cytometry, expression
of TAZ(S89A) induced an en masse enlargement of the
CD44high/CD24low population (Figures 4A and S4B), resembling
MIV and MDA-MB-231 cells (Figure 4B). Functionally, MII-
TAZ(S89A) formed more primary, secondary, and tertiary mam-
mospheres than control cells (Figure 4C). Of note, this was not
accompanied by increased proliferation, as the sizes of mam-
mospheres were similar in control and TAZ(S89A)-expressing
cells (Figure 4D).
To directly show that activated TAZ is sufficient to endow
CSC-like properties to non-CSCs, MII cells were transduced
with expression vectors encoding for a doxycycline-inducible
TAZ(S89A) or enhanced green fluorescent protein (EGFP)
as control. Transduced cells were FACS-sorted into CD44high/
CD24low and CD44low/CD24low populations, cultured in the pres-
ence or absence of doxycycline, and assayed formammosphere
formation (see diagram in Figure 4E). CD44high/CD24low cells
increased their self-renewal potential after activation of TAZCell 147, 759–772, Nexpression (Figure 4F, compare lane 6
with 8). More remarkably, TAZ(S89A)
promoted abundant secondary mammo-
sphere formation in the CD44low/CD24low
population, making it indistinguishablefrom the CD44high/CD24low cell population (Figure 4F, compare
lanes 5, 7, and 8). This effect was specific, as a similar shift
was not observed in doxycycline-treated MII-EGFP cells. These
findings suggest that TAZ activity can confer attributes of self-
renewal to the more differentiated progeny of prospective CSC
populations.
In addition to self-renewal, another characteristic of CSCs is
their capacity to resist chemotherapy (Dean et al., 2005). We
noticed that TAZ overexpression in MII cells increased the
activity of multidrug resistance (MDR) proteins, as revealed by
the 4-fold increase of the SP (Figures 4G and S4C). Consistently,
TAZ-expressing cells were more resistant than control cells to
two widely used chemotherapeutic drugs, Doxorubicin and
Paclitaxel (Figures 4H and S4D). The latter result is consistent
with the recently reported dependency of MDA-MB-231 cells
on TAZ for Taxol resistance (Lai et al., 2011).
TAZ Promotes the Formation of High-Grade Tumors
Data presented so far indicate that raised levels of TAZ are
instrumental for several phenotypic traits so far associated
with the behavior of prospective CSC populations in vitro.
Because in vivo CSCs are defined operationally by their ability
to seed new tumors at limiting dilutions (Visvader and Lindeman,
2008), we determined whether TAZ activation promotes theovember 11, 2011 ª2011 Elsevier Inc. 763
Figure 4. TAZ Endows Self-Renewal Capacity to Breast Cancer Cells
(A) Representative FACS profiles with CD24 and CD44 markers of MII cells transduced with control (empty vector) or TAZ(S89A)-encoding retroviral vectors. See
Figure S4B for quantifications.
(B) Representative FACS profiles of MIV and MDA-MB-231 cells with CD24 and CD44 markers. In contrast to parental MII cells, only the CD44high/CD24low cell
population is discernible after FACS in these cell lines.
(C and D) Effects of stable TAZ activation on the mammosphere-forming abilities of MII cells. (C) Quantification of primary, secondary, and tertiary mammo-
spheres formed by MII-empty vector or MII-TAZ(S89A) cells (mean + SEM of six experiments). (D) Representative images of primary mammospheres. Scale bars
represent 200 mm.
(E and F) Forced expression of TAZ(S89A) enhances mammosphere formation in the CD44low/CD24low cell population. (E) Schematic representation of the
experiments. Cells were transduced with vectors encoding for the reverse tetracycline-dependent transactivator (rtTA) and for a doxycycline-inducible
TAZ(S89A) or EGFP. Doxycycline was used at 0.5 mg/ml. (F) Quantification of secondary mammospheres formed by the eight cell groups shown in (E). Data are
presented as in (C).
(G and H) TAZ confers partial drug resistance. (G) Quantification of the SP (Hoechst-low) in control or TAZ(S89A)-expressing MII cells. We used this assay
because chemoresistance is linked to increased activity of MDR proteins that are also responsible for the Hoechst exclusion phenomena. To ensure MDR
involvement, MII-TAZ(S89A) cells were pretreated with the MDR1 inhibitor Verapamil. Data are reported as mean + SEM. See also Figure S4C for FACS data. (H)
Dose-response curves of MII-empty vector and MII-TAZ(S89A) cells treated with Paclitaxel. Bars denote the standard error (n = 4).
See also Figure S4.
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Figure 5. TAZ Promotes the Formation of High-Grade Tumors and Is Overexpressed in G3 Primary Human Tumors
(A) Tumor-seeding ability of MII-empty vector and MII-TAZ(S89A) cells. The indicated number of cells were injected into the fat pads of RAG/mice. Results are
shown as the fraction of mice developing palpable tumors 5 weeks after transplantation. The complete set of data is in Figure S5A.
(B and C) Representative hematoxylin and eosin staining of tumors emerging from fat-pad injection of MII-empty vector (B) and MII-TAZ(S89A) cells (C).
(D) Frequency of TAZ-positive G1 or G3 primary human breast cancers as judged by immunohistochemistry (IHC). Tumors were scored as positive when over
10% of cells displayed nuclear TAZ staining similar to or stronger than that of the cells of normal ducts included in the same section. 35/44 G3 tumors and only
1/26 G1 tumor were found positive for TAZ expression (p value < 0.0001).
(E and F) Representative IHC pictures for TAZ expression in G1 (E) or G3 (F) invasive human breast cancer samples. Nuclei are counterstained with hematoxylin.
Black arrowheads in (E) point to the TAZ-positive cells of the normal mammary ductal tissue (NT) included in the same section with G1 tumor structures (G1). Inset
in (E) shows (white arrowhead) very rare TAZ-positive cells that are seldom associated with G1 tumors. Further pictures of TAZ staining of G1 and G3 tumors are
shown in Figures S5C and S5D.
(G) Frequency of amplification of the TAZ locus, WWTR1, in breast cancers from the EMC dataset stratified according to the TAZ/YAP signature.
(H) Box-and-whisker plots comparing TAZ mRNA expression between primary breast tumors from the EMC dataset with or without amplifications in the
TAZ-encoding locus.
See also Figure S5.formation of tumor-initiating cells. As shown in Figures 5A
and S5A, palpable tumor masses developed in mice injected
with >3 3 105 control or MII-TAZ(S89A) cells, although ata considerably higher frequency in the TAZ-expressing cells;
in contrast, only MII-TAZ(S89A) cells formed tumors when as
few as 104 cells were injected. Interestingly, this increase inCell 147, 759–772, November 11, 2011 ª2011 Elsevier Inc. 765
Figure 6. TAZ Is Required downstream of EMT for Self-Renewal of Breast Cancer Cells
(A and B) The CD44high/CD24low population of MII cells display EMT features. (A) Immunofluorescence (IF) images for the epithelial marker E-Cadherin and the
mesenchymal marker Vimentin in FACS-sorted CD44low/CD24low and CD44high/CD24low populations of MII cells. Nuclei are stained with Hoechst. (B) Western
blot analysis for E-Cadherin and TAZ expression in the same cell populations described in (A).
(C) Representative IF pictures of E-Cadherin in the indicated MII cell derivatives.
(D) Quantification of primary and secondary mammospheres formed by the indicated cells (mean of six replica experiments + SEM).
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tumor-initiation capacity was accompanied by increased size
and histological grade of the tumors. Control MII cells formed
small tubular carcinomas displaying no nuclear atypia, mostly
resembling human G1 tumors (Figure 5B). Conversely, the MII-
TAZ(S89A) cells formed invasive carcinomas that phenocopy
several traits of human G3 breast cancers, such as lack of
tubular structures, high nuclear pleomorphism, and prominent
nucleoli (Figure 5C and data not shown). Thus, TAZ promotes
tumorigenic potential and the acquisition of a more malignant
and less differentiated phenotype.
TAZ Protein Is Overexpressed in High-Grade Breast
Cancers
Because TAZ protein levels correlate with tumorigenic potential
in our cellular model systems, we next used immunohistochem-
istry to examine TAZ expression in human primary tumor
samples. We compared 26 G1 and 44 G3 invasive ductal carci-
nomas. In G1 tumors, TAZ expression was typically hardly
detectable (Figures 5D, 5E, and S5B), with strong staining ap-
pearing only on rare individual cells (Figure 5E, inset). In contrast,
the vast majority of G3 tumors (80%) contained a substantial
fraction of cells displaying an intense TAZ nuclear staining
(Figures 5D, 5F, and S5C). The frequency of TAZ-positive tumors
in this analysis recapitulates the frequency of G3 tumors with
high TAZ/YAP activity as assayed by TAZ/YAP target gene
expression in patients’ datasets (82%, data not shown). Thus,
G3 breast cancers are enriched with TAZ-expressing cells,
a finding that links the increased CSC content of high-grade
tumors (Pece et al., 2010) with the present functional character-
ization of TAZ as a promoter of CSC-like traits.
The TAZ-Encoding Locus Is Amplified in a Fraction
of Breast Cancers
We next wondered about the mechanisms leading to increased
TAZ expression in breast cancer. First, by analyzing the EMC
dataset that contains combined clinical, gene-expression, and
comparative genomic hybridization (CGH) data, we investigated
whether the TAZ-encoding locusWWTR1 is amplified in primary
tumors (Zhang et al., 2009). Notably, 27 out of 313 tumors exhibit
evidence of amplification at the WWTR1 locus, the majority of
which (22) belong to the group showing high TAZ/YAP activity
(Figure 5G). An essential criterion for establishing whether an
amplified gene might contribute to tumorigenesis is that its
mRNA has to be overexpressed in the tumors where it is ampli-
fied. In agreement with this prediction, we found that TAZ mRNA
levels are specifically increased in tumors with amplifiedWWTR1
(Figure 5H).
Although amplification provides the proof-of-principle for
a biological selectivemechanism leading to TAZ overexpression,(E) Western blot analysis for TAZ, CTGF, Survivin, and E-Cadherin expression inM
(shGFP) or two independent TAZ-targeting (shTAZ#2 and shTAZ#3) shRNAs.
(F) Quantification of primary and secondary mammospheres formed by the MDA
(G) Representative phase-contrast images of control or TAZ-depleted MDA-MB-
(H) Western blot analysis of lysates from control or Twist-expressing HMLE cells
anti-TAZ siRNAs (see main text). Note how depletion of TAZ in HMLE-Twist cells
(I) Quantification ofmammospheres formed by HMLE-empty vector or HMLE-Twis
are reported as in (D).
See also Figure S6.the relatively low frequency of this event (14% of G3 tumors)
contrasts with the previous immunohistochemical and bio-
informatic analyses (Figures 1B and 5D–5F), indicating increased
TAZ protein levels and activity in at least 80% of G3 tumors. This
indicates that other mechanismsmust be in place to elevate TAZ
levels during tumor progression in the larger fraction of breast
cancers.
EMT Promotes Self-Renewal through TAZ
The biological activity of TAZ in breast cancer cells presents
intriguing analogies with the cellular traits acquired after an
EMT (Thiery et al., 2009): both TAZ and EMT promote the forma-
tion of cell populations enriched with CSCs, as assayed by
tumor-seeding ability, mammosphere formation, and expression
of cell-surface markers (Mani et al., 2008 and this study). EMT
and TAZ activity are linked: we found that cells displaying high
levels of endogenous TAZ protein, such as the CD44high/CD24low
fraction ofMII or MIV andMDA-MB-231 cells, also display loss of
junctional E-Cadherin (Figures 6A, 6B, and S6A), which is a hall-
mark of the EMT process (Thiery et al., 2009). Moreover, as
shown previously—and repeated here—overexpression of TAZ
can trigger EMT (Chan et al., 2008; Lei et al., 2008) (Figure 6C).
We thus asked whether a cardinal feature of CSCs, i.e., self-
renewal potential, is induced by TAZ because TAZ induces
EMT or, rather, if TAZ is downstream of EMT and serves as a
molecular mediator of its pro-stemness effects. For this, we
overexpressed E-Cadherin in MII-TAZ(S89A) cells (Figure 6C),
but this had no effect on the generation of primary and sec-
ondary mammospheres from these cells (Figure 6D). This sug-
gested that TAZ promotes self-renewal of breast cancer cells
independently of loss of junctional E-Cadherin.
Next, we tested whether TAZ is required for the EMT pheno-
type and for EMT-induced self-renewal. For this, we used
MDA-MB-231 cells that displayed an overt mesenchymal
phenotype and expressed high levels of endogenous TAZ (Fig-
ure 2C). As shown in Figures 6E–6G, loss of TAZ dramatically
affected TAZ target gene expression as well as primary and
secondary mammosphere formation from MDA-MB-231 cells
but did not change their mesenchymal morphology or induce
E-Cadherin expression.
To extend our study to nontransformed cells, we used
immortalized human mammary epithelial cells (HMLEs) and
induced EMT by ectopic overexpression of the transcription
factor Twist (Mani et al., 2008) (Figure 6H). As previously re-
ported, HMLE-Twist cells displayed a >5-fold increased mam-
mosphere-forming capacity than empty vector control cells
(Figure 6I) (see Mani et al., 2008). Interestingly, TAZ protein
levels, but not mRNA levels, were also significantly upregulated
in HMLE-Twist cells, leading to TAZ-dependent induction ofDA-MB-231 cells stably transducedwith retroviral vectors expressing a control
-MB-231 derivatives described in (E). The data are reported as in (D).
231 cells.
. Where indicated, cells were transfected with a control or three independent
did not rescue E-Cadherin expression.
t cells transiently transfected with control or anti-TAZ siRNAs as in (H). The data
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Figure 7. Scribble Delocalization Activates TAZ by Inhibiting the Hippo Pathway
(A) Western blot analysis for Scribble, TAZ, CTGF, and E-Cadherin expression in MII cells transfected with control or three independent anti-Scribble siRNAs.
Scribble loss increases TAZ protein levels and activity without affecting E-Cadherin expression.
(B) Western blot for the indicated proteins in lysates of MII-empty vector and MII-Snail cells transfected with control or Scribble siRNA#3 (SCRIB siRNA).
(C) Confocal images showing localization of Scribble in control or Snail-expressingMII cells. For each cell line, panels show XY images (top) and the indicated (red
line) Z stacks (bottom). White arrowheads point to lateral membrane domains. Nuclei are stained with propidium iodide (PI).
(D) Western blot analysis for Scribble, TAZ, CTGF, and Survivin expression in lysates of MII cells transduced with a retroviral vector coding for ScribP305L.
Expression of ScribP305L causes an increase of total Scribble levels and the displacement of this protein from the lateral plasma membrane (see Figure S7E).
(E) Scheme of the proposed epistatic relationships between EMT, Scribble, TAZ, and self-renewal.
(F) Quantification of secondary mammospheres formed by control or ScribP305L-expressing MII cells. Data are mean of six replica experiments + SEM.
(G) CoIP/western blot analysis of MII cell lysates showing endogenous TAZ bound to Scribble, MST2, and LATS1. As a specificity control, immunoprecipitation
was repeated with unrelated mouse IgG.
768 Cell 147, 759–772, November 11, 2011 ª2011 Elsevier Inc.
CTGF, Survivin, and PAI-1 (Figures 6H and S6B). We confirmed
that TAZ can be induced by EMT also in MII cells ectopically
expressing Snail (Figure S6C). Crucially, in HMLE-Twist cells,
TAZ knockdown significantly reduced the Twist-induced
mammosphere-forming ability (Figure 6I) but did not alter the
Twist-induced mesenchymal phenotype (Figure 6H and data
not shown).
We conclude from these experiments that levels of en-
dogenous TAZ protein increase during EMT and that TAZ is
a relevant mediator of the mammosphere-forming capacity
promoted by EMT in both nontumorigenic and transformed
epithelial cells.
Scribble Delocalization Activates TAZ
Although full EMT is rare in human tumors, most carcinomas
show evidence of a partial EMT (Savagner, 2010). As such, it
appears that cancer cells exploit only the onset of the EMT
program without the need to reach a completely mesenchymal
state. This partial EMT invariably entails loss of apicobasal
polarity and destabilization of junctional complexes (Thiery
et al., 2009). A key gatekeeper of epithelial polarity is Scribble,
which establishes the basolateral domain of the cell membrane
(Macara, 2004). Scribble is frequently disabled during mammary
tumorigenesis and also serves as a tumor suppressor in
Drosophila (Zhan et al., 2008; Humbert et al., 2008). Interestingly,
in fly tissues, the overgrowth of scribblemutant clones is depen-
dent on yorkie, the TAZ Drosophila ortholog (Grzeschik et al.,
2010); yet, the molecular mechanisms of this genetic interaction
remain unknown.
With this background in mind, we tested whether Scribble is
a relevant inhibitor of TAZ in breast cancer cells. As shown in Fig-
ure 7A, Scribble knockdown in MII cells resulted in robust upre-
gulation of TAZ protein levels but not mRNA levels and did not
affect epithelial morphology (Figures S7A and S7B). Notably,
Scribble regulates TAZ in epithelial cells but not after Snail-
induced EMT (Figure 7B); this reinforces the notion that Scribble
inactivation is part of the EMT program necessary for TAZ
upregulation.
We next wondered what the mechanism is by which EMT
inhibits Scribble. EMT did not affect Scribble protein levels (Fig-
ure S7C) but dramatically changed its subcellular localization: in
MII and HMLE cells, Scribble is localized to the basolateral
membrane, but after expression of Snail or Twist, it is excluded
from this domain and becomes predominantly cytoplasmic
(Figures 7C and S7D). This raised the possibility that the delocal-
ization of Scribble could be sufficient for TAZ induction in breast
cancer. To test this, MII cells were transduced with a mutant
version of Scribble (ScribP305L) that is not localized to the cell
membrane and even disrupts membrane recruitment of endog-
enous Scribble (Zhan et al., 2008) (Figure S7E). We found that(H) Western blot analysis of TAZ immunocomplexes purified from control, SCRI
CoIPs.
(I) Scribble depletion and EMT disable TAZ interaction with b-TrCP as verified by
(J) Western blots for the indicated proteins in lysates from MII cells expressing
Scribble siRNA#3 (SCRIB siRNA).
(K) A model depicting the proposed mechanism for TAZ regulation by Scribble a
See also Figure S7.ScribP305L induced TAZ protein levels and activity (Figure 7D).
Conversely, overexpression of a membrane-tethered version
of Scribble, but not of wild-type Scribble, strongly inhibited
TAZ expression and activity in MII-Snail cells (Figures S7F
and S7G).
The data thus suggest a scenario whereby EMT leads to
Scribble delocalization from the cell membrane and, in so doing,
relieves TAZ from Scribble inhibition to promote CSC-related
traits (Figure 7E). In agreement with this scenario, expression
of ScribP305L increased the self-renewal potency of MII cells,
as assayed by second-generation mammosphere formation
(Figure 7F). Moreover, the CD44high/CD24low subpopulation of
MII cells—enrichedwith CSC-like cells—is also specifically char-
acterized by loss of junctional Scribble, correlating with their
elevated levels of endogenous TAZ (Figure S7H). This was also
verified in MIV and MDA-MB-231 tumor cells (Figure S7I).
Scribble Regulates the Hippo Pathway
in Breast Cancer Cells
TAZ is the downstream effector of the Hippo pathway. This
signaling cascade is controlled by two evolutionarily conserved
kinases, MST1/2 and LATS1/2. MST1/2 (the homologs of
Drosophila Hippo) phosphorylate LATS1/2 that, in turn, phos-
phorylate and thereby inhibit TAZ and YAP. Loss of this negative
control stabilizes TAZ and promotes its nuclear activity (Pan,
2010). However, the biochemical mechanisms by which the
Hippo signal transduction pathway is regulated upstream of
MST remain poorly understood. Our findings on TAZ inhibition
by Scribble raised the attractive possibility that Scribble func-
tions as an upstream regulator of Hippo signaling in breast
cancer cells. Remarkably, in coimmunoprecipitation (coIP)
assays of endogenous proteins, we found that TAZ forms a
biochemical complex with MST, LATS, and Scribble itself in
both MII and HMLE cells (Figures 7G and S7J).
We thus askedwhether Scribble is required for the recruitment
of MST and/or LATS to TAZ. Interestingly, the interaction
between TAZ and LATS was only weakened in coIP from
Scribble-depleted cells; in contrast, Scribble was required for
the recruitment of MST2 to the TAZ/LATS complex (Figure 7H,
compare lanes 1 and 2; see also Figures S7J and S7K). Accord-
ingly, in TAZ immunoprecipitates, MST-mediated phosphoryla-
tion of LATS on S909—and LATS-mediated phosphorylation of
TAZ— were lost upon Scribble knockdown. Thus, Scribble is
required for the assembly of a complex between TAZ, LATS,
and MST and for MST-dependent activation of the LATS kinase.
In line with the notion that EMT regulates this pathway, induction
of EMT in MII and HMLE cells blocked TAZ association to
Scribble and recapitulated the biochemical consequences of
Scribble inactivation (Figure 7H, lane 3; see also Figures S7J
and S7K).B siRNA#3-transfected, or Snail-MII cells. See Figure S7K for inputs of these
western blot analysis on TAZ immunocomplexes described in (G).
wild-type mTAZ or TAZS89/306A, transfected with control (Control siRNA) or
nd the Hippo pathway.
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It is known that TAZ phosphorylation by LATS on S306
promotes its degradation through association to the b-TrCP E3
ubiquitin-ligase complex (Liu et al., 2010) (Figure S7L). We found
that TAZ interacted with b-TrCP at the endogenous level in MII
cells (Figure 7I, lane 1). Crucially, Scribble knockdown or EMT
induction impaired the formation of such a TAZ/b-TrCP complex
(Figure 7I, lanes 2 and 3). Furthermore, LATS-mediated phos-
phorylation is essential for TAZ regulation by Scribble, as
a mutant TAZ missing LATS phosphorylation sites (S89 and
S306) is insensitive to loss of Scribble (Figure 7J). Thus, in epithe-
lial cancer cells, Scribble is an upstream activator of the Hippo
pathway leading to TAZ inhibition. Scribble inactivation upon
EMT allows TAZ to escape this inhibition and accumulate in
stem-like progenitors resulting in more aggressive tumors (see
diagram in Figure 7K).
DISCUSSION
TAZ Is a Molecular Determinant of Biological Properties
Associated with Breast CSCs
We found that TAZ protein levels and TAZ biological activities
go hand-in-hand with some salient traits that have been associ-
ated with CSCs. The following evidence supports this conclu-
sion: (1) the molecular imprints of TAZ/YAP activity are tightly
linked with progression from well-differentiated to high-grade
tumors, during which the CSC content has been shown to
increase (Pece et al., 2010); indeed, low-grade G1 tumors have
low numbers of TAZ-positive cells that greatly increase in G3
tumors; (2) TAZ protein levels are specifically enriched in
prospective CSCs purified by cell sorting from genetically
identical heterogeneous cell populations; (3) in human tumors,
TAZ activity is associated with molecular signatures of stem
cells; (4) TAZ activity is a clinically relevant tool to predict the
proclivity to develop metastasis, itself another hallmark of CSC
activity.
At the functional level, we show that endogenous TAZ is
required for self-renewal and tumor-initiation properties in breast
cancer cells, and that raising TAZ levels promotes these CSC-
related traits. Increased TAZ activity is sufficient to convert
otherwise benign experimental tumors into a more aggressive
G3-like histopathological phenotype. Thus, TAZ expression
levels and activity embody three characteristics that have
traditionally been linked to CSCs in breast tumors, i.e., tumor
heterogeneity, reduced differentiation, and tumor-seeding
potential.
One unsettled issue in the CSC field is whether the potential of
self-renewal is an exclusive property of CSCs, or whether plas-
ticity exists in these hierarchical lineages, such that any cell,
even a non-CSC, could acquire self-renewal potential under
appropriate intrinsic or extrinsic cues (Chaffer and Weinberg,
2011; Gupta et al., 2009). Interestingly, it has been recently
demonstrated that non-stem mammary epithelial cells could
spontaneously revert to a stem-like state in a seemingly
stochastic manner (Chaffer et al., 2011). The data presented
here show that a molecular player could induce a similar type
of transition: TAZ activation in non-CSCs could reactivate their
self-renewal potential, suggesting that TAZ levels may regulate
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Experimentally induced EMT instills stem-like properties to
mammary epithelial cells. As such, EMT has been evoked as
the culprit for tumor progression and tumor heterogeneity
(Chaffer and Weinberg, 2011; Mani et al., 2008; Thiery et al.,
2009). We found that TAZ is turned on by overexpression of
the EMT-inducing transcription factors Twist or Snail and is
required for self-renewal induced by Twist. Others have shown
that TAZ itself can sustain EMT (Chan et al., 2008; Lei et al.,
2008); however, we found that acquisition of mesenchymal
traits can be uncoupled from TAZ-induced CSC-like properties.
Indeed, attenuation of endogenous TAZ has no effect on Twist-
induced mesenchymal transition of nontransformed mammary
cells or on the intrinsic mesenchymal phenotypes of malignant
cells. We thus envision TAZ-induced EMT as an embedded
self-sustaining mechanism of TAZ activity. Importantly, neither
stabilization of TAZ protein levels nor induction of self-renewal
require the entire EMT program. In fact, only a specific segment
of EMT, the loss or delocalization of the cell-polarity determinant
Scribble, is necessary, with loss of Scribble increasing TAZ
activity and CSC properties without inducing overt mesenchym-
alization. Conversely, adding back a membrane-tethered
version of Scribble in post-EMT/Snail-expressing cells is suffi-
cient to destabilize TAZ without modifying their mesenchymal
phenotype (data not shown). These findings also offer a plausible
explanation for a conundrum regarding the role of EMT in high-
grade malignancies, as transition of epithelial cells toward a full
mesenchymal cell fate is rare in cancers (Chaffer and Weinberg,
2011; Savagner, 2010). However, if we consider EMT ‘‘only’’ in
terms of loss of apicobasal polarity that results in TAZ stabiliza-
tion, then this conundrum would be resolved because disruption
of cell polarity and tissue organization is a fundamental trait
present in the majority of human tumors. Although intriguing,
a more definitive demonstration of this possibility must await
dedicated in vivo studies.
It is worth considering what other signals may drive TAZ
activity in addition to EMT. For example, structural/physical
properties of the tumor microenviroment are just as relevant as
soluble cues in driving progression (Butcher et al., 2009). Indeed,
we recently discovered a central role for TAZ/YAP in mechano-
transduction (Dupont et al., 2011), raising the interesting
possibility that TAZ may be locally activated at specific ‘‘biome-
chanical niches’’ within tumors.
A Mechanism that Links Cell Polarity to Hippo Signaling
TAZ and YAP are central mediators of the Hippo pathway, which
regulates organ size from Drosophila to mammals (Pan, 2010).
How this pathway responds to extracellular signals remains
unclear. Further evidence points to cell adhesion and polarity
proteins as likely candidates of Hippo pathway activation, but
the underlying biochemical mechanisms remain an unsolved
mystery. In the present study, we found that in nontransformed
and tumorigenic mammary epithelia, the Hippo cascade is acti-
vated by Scribble at the cell-cell contact. Scribble serves as an
adaptor to assemble a protein complex with TAZ, LATS, and
MST and is required for MST-dependent activation of LATS
and ultimately TAZ phosphorylation (Figure 7K). Indeed, Scribble
is frequently delocalized from the cell membranes in breast
cancer (Zhan et al., 2008), and we now show that mimicking this
subcellular relocalization event is sufficient to allow TAZ to
escape LATS inhibition.
In addition to the basolateral Scribble complex, the establish-
ment of epithelial apicobasal polarity is mediated by the apical
Crumbs and Par/aPKC complexes. Apical and basolateral
complexes mutually regulate each other, leading to the segrega-
tion of the apical and basolateral membranes (Humbert et al.,
2008; Macara, 2004). We suggest that basolateral polarity
controlled by the Scribble complex is the primary polarity signal
that activates the Hippo cascade in mammary epithelia. This
offers a remarkably simple mechanism by which cell polarity
can control cell fates through the Hippo pathway, whereby the
degree of Hippo activation is proportional to the extent of the
cell basolateral domain. Although the generality of this concept
must await validation in other contexts, genetic evidence in
Drosophila is consistent with this idea: deregulation of Crumbs,
gain of active forms of aPKC, or mutation in Scribble or other
members of the Scribble complex all lead to a yorkie-dependent
hyperproliferation (Grzeschik et al., 2010; Robinson et al., 2010).
Understanding tumor formation is ultimately directed to cure
patients. Unfortunately, the option of targeting the core Hippo
cascade for breast cancer therapies is presently frustrated by
the fact that the known kinases are negative regulators of TAZ,
as these would need to be activated to counteract tumor
progression. However, the present study pinpoints extrinsic
and intrinsic cellular determinants upstream of the core signaling
cascade, which could be exploited to curb tumorigenic potential.
EXPERIMENTAL PROCEDURES
Gene-Expression Analysis
Gene-expression profiles from seven breast cancer datasets analyzed on
Affymetrix HG-U133A arrays and annotated with histological tumor grade
and clinical outcome were downloaded from NCBI Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/). A list of these datasets is provided
in Table S2. After reorganization, microarray data were merged in a compen-
dium (metadataset) comprising 993 unique samples (see Extended Experi-
mental Procedures). Expression values of the metadataset were generated
from raw CEL files using RMA algorithm implemented by the affy R package
(Irizarry et al., 2003). The type and content of clinical and pathological annota-
tions of the metadataset samples were derived from the original cohorts.
Genes upregulated in histological G3 tumors were identified, comparing the
expression profiles of G3 versus G1 samples with SAM algorithm coded in the
samr R package (Tusher et al., 2001).
Detailed statistical methods are provided in the Extended Experimental
Procedures.
Enrichment Analysis of Signaling Pathways and Stem Cell
Signatures
We used an over-representation analysis based on Fisher’s exact test to
assess the statistical association between genes overexpressed in histological
G3 tumors and gene signatures of signal transduction pathways. The signifi-
cance of such association was evaluated, taking into account the number of
genes in the two lists and the total number of genes in the microarray. Under
the null hypothesis that the proportion of probesets overexpressed in G3
samples and present in the gene signature is smaller than or equal to the
proportion of probesets that are not contained in the gene signature (one-
sided test), we built a 2 3 2 contingency table for each gene signature
recording the relation between the genes in the signature and the genes over-
expressed in histological grade 3. Givenm probesets in the G3-enriched gene
set and n probesets in a predefined pathway signature, the probability ofobserving an overlap of k probesets for that gene signature, under the hypoth-
esis that them probesets were picked out randomly from theN total probesets
of the microarray, is given by the hypergeometric distribution. For any given
signature, the significance of the observed overlap k (p value) is computed
as the sum of the probabilities for all possible contingency tables with an over-
lap greater than or equal to k. The null hypothesis is then rejected if the p value
is smaller than a predetermined threshold a (e.g., a% 0.05). Considering that
multiple signatures are being tested, p values can be finally adjusted for false
discovery rate (FDR) using, e.g., Benjamini-Hochberg correction.
The over-representation analysis has been conducted using the phyper
function of the R stats package. The p value threshold has been set to 0.05
and p values adjusted using the p.adjust function of the R stats package
(FDR < 5%).
Mammosphere Assays
Confluent monolayers of cells were trypsinized, counted, and plated as single-
cell suspensions (1000 cells/cm2) on ultra-low attachment plates (Costar).
Mammospheres were counted after 5 days; cells were thereafter dissociated
to be reseeded for a second round of mammosphere formation. Mammo-
sphere cultures of MII, HMLE, MDA-MB-231, and their derivatives were per-
formed as described in Dontu et al. (2003); for MIV cells, culture conditions
were as in Ponti et al. (2005). Statistical analyses were done with Prism soft-
ware (GraphPad).
Fluorescence-Activated Cell Sorting
Cells were detached from plates with TrypLE (Invitrogen), resuspended (5 3
105 cells/ml), incubated in running buffer (PBS 13, BSA 0.5%, and EDTA
5 mM) with anti-human CD44 (clone G44-26, FITC-conjugated, BD Biosci-
ences) and anti-human CD24 (clone ML5, PE-conjugated, BD Biosciences),
and finally analyzed on a MoFlo XDP sorter (Beckman Coulter).
Tumorigenesis Assays
For xenograft tumor-seeding studies, the indicated numbers of MII or MIV cells
were suspended in 100 ml Matrigel (BD Biosciences) and injected in the fat
pads of immunocompromized female mice. Tumor formation was assayed
by palpation. After the indicated periods, mice were sacrificed and tumors
were explanted for histological analyses as previously described (Adorno
et al., 2009).
Numbers of tumor-initiating cells were estimated by using ELDA software
(http://bioinf.wehi.edu.au/software/elda/).
Western Blot and Immunoprecipitations
Protein lysates were obtained from cells grown for 2 days at high density, after
sonication in lysis buffer (20 mM HEPES [pH 7.8], 100 mM NaCl, 5% glycerol,
5 mM EDTA, 0.5% Np40, and protease and phosphatase inhibitors). The
western blot procedure was carried out as described in Dupont et al. (2009).
Primary antibodies are listed in the Extended Experimental Procedures.
Immunoprecipitations were carried out as in Adorno et al. (2009), with the
following modifications: extracts were diluted to 20 mM HEPES (pH 7.8),
100 mM NaCl, 5% glycerol, 2.5 mM MgCl2, 1% Triton X-100, 0.5% NP40
and incubated with protein A-sepharose-bound anti-TAZ/YAP monoclonal
antibody (Santa Cruz, sc-101199).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and three tables and can be found with this article online at
doi:10.1016/j.cell.2011.09.048.
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